Journal article
Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario
Abstract
PURPOSE: To evaluate the 21-gene recurrence score (RS) on decision-making in a population-based cohort.
PATIENTS AND METHODS: Patients with axillary node-negative or nodal micrometastases, estrogen receptor-positive, and human epidermal growth factor receptor 2-negative breast cancer being considered for chemotherapy were eligible. All cancer treatment centers in Ontario, Canada, participated. Oncologists made a preliminary recommendation for …
Authors
Levine MN; Julian JA; Bedard PL; Eisen A; Trudeau ME; Higgins B; Bordeleau L; Pritchard KI
Journal
Journal of Clinical Oncology, Vol. 34, No. 10, pp. 1065–1071
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
April 1, 2016
DOI
10.1200/jco.2015.62.8503
ISSN
0732-183X
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsAxillaBiomarkers, TumorBreast NeoplasmsBreast Neoplasms, MaleChemotherapy, AdjuvantClinical Decision-MakingDecision MakingFemaleGene Expression ProfilingGenotypeHumansLymph NodesLymphatic MetastasisMaleMiddle AgedNeoplasm MicrometastasisNeoplasm Recurrence, LocalNeoplasm StagingOntarioPatient SatisfactionPredictive Value of TestsProspective StudiesReceptor, ErbB-2Receptors, EstrogenRisk AssessmentRisk FactorsUncertainty